Melanoma Clinical Trials in Boston

Showing 121-140 of 219 trials

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

Uveal MelanomaOcular MelanomaChoroidal Melanoma

Aura Biosciences57 participantsStarted Feb 2017

Tucson, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +10 more locations

TERMINATEDPhase 1< 1 mile

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

NCT04244552

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.

Breast CancerColorectal CancerOvarian Cancer+13 more

Atreca, Inc.87 participantsStarted Feb 2020

Phoenix, Arizona, United States • Tucson, Arizona, United States • Duarte, California, United States +16 more locations

Study in Subjects With Small Primary Choroidal Melanoma

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Melanoma Trials in Other Cities

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Optical Frequency Domain Imaging for Non-melanoma Skin Cancers

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Other Conditions in Boston